These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 33372875)

  • 21. APOE-ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals.
    Brugulat-Serrat A; Sánchez-Benavides G; Cacciaglia R; Salvadó G; Shekari M; Collij LE; Buckley C; van Berckel BNM; Perissinotti A; Niñerola-Baizán A; Milà-Alomà M; Vilor-Tejedor N; Operto G; Falcon C; Grau-Rivera O; Arenaza-Urquijo EM; Minguillón C; Fauria K; Molinuevo JL; Suárez-Calvet M; Gispert JD;
    EJNMMI Res; 2023 Mar; 13(1):18. PubMed ID: 36856866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia.
    Salvadó G; Grothe MJ; Groot C; Moscoso A; Schöll M; Gispert JD; Ossenkoppele R;
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2212-2224. PubMed ID: 33521872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice.
    Pankiewicz JE; Guridi M; Kim J; Asuni AA; Sanchez S; Sullivan PM; Holtzman DM; Sadowski MJ
    Acta Neuropathol Commun; 2014 Jun; 2():75. PubMed ID: 24972680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer's disease: a cohort study.
    Mattsson N; Ossenkoppele R; Smith R; Strandberg O; Ohlsson T; Jögi J; Palmqvist S; Stomrud E; Hansson O
    Alzheimers Res Ther; 2018 Aug; 10(1):77. PubMed ID: 30086796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern.
    Risacher SL; Kim S; Nho K; Foroud T; Shen L; Petersen RC; Jack CR; Beckett LA; Aisen PS; Koeppe RA; Jagust WJ; Shaw LM; Trojanowski JQ; Weiner MW; Saykin AJ;
    Alzheimers Dement; 2015 Dec; 11(12):1417-1429. PubMed ID: 25960448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals.
    Yan S; Zheng C; Paranjpe MD; Li Y; Li W; Wang X; Benzinger TLS; Lu J; Zhou Y
    Brain; 2021 Nov; 144(10):3201-3211. PubMed ID: 33876815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.
    Drzezga A; Grimmer T; Henriksen G; Mühlau M; Perneczky R; Miederer I; Praus C; Sorg C; Wohlschläger A; Riemenschneider M; Wester HJ; Foerstl H; Schwaiger M; Kurz A
    Neurology; 2009 Apr; 72(17):1487-94. PubMed ID: 19339712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aβ-related memory decline in APOE ε4 noncarriers: Implications for Alzheimer disease.
    Lim YY; Laws SM; Villemagne VL; Pietrzak RH; Porter T; Ames D; Fowler C; Rainey-Smith S; Snyder PJ; Martins RN; Salvado O; Bourgeat P; Rowe CC; Masters CL; Maruff P
    Neurology; 2016 Apr; 86(17):1635-42. PubMed ID: 27029632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alzheimer's disease genetic risk and cognitive reserve in relationship to long-term cognitive trajectories among cognitively normal individuals.
    Pettigrew C; Nazarovs J; Soldan A; Singh V; Wang J; Hohman T; Dumitrescu L; Libby J; Kunkle B; Gross AL; Johnson S; Lu Q; Engelman C; Masters CL; Maruff P; Laws SM; Morris JC; Hassenstab J; Cruchaga C; Resnick SM; Kitner-Triolo MH; An Y; Albert M
    Alzheimers Res Ther; 2023 Mar; 15(1):66. PubMed ID: 36978190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Performance on complex memory tests is associated with β-amyloid in individuals at risk of developing Alzheimer's disease.
    Kjeldsen PL; Damholdt MF; Madsen LS; Nissen PH; Aanerud JFA; Parbo P; Ismail R; Kaasing M; Eskildsen SF; Østergaard L; Brooks DJ
    J Neuropsychol; 2024 Mar; 18(1):120-135. PubMed ID: 37382036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Moderating effect of
    Hwang JY; Byun MS; Choe YM; Lee JH; Yi D; Choi JW; Hwang SH; Lee YJ; Lee DY;
    Neurology; 2018 Mar; 90(13):e1167-e1173. PubMed ID: 29490913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aβ amyloid, cognition, and APOE genotype in healthy older adults.
    Lim YY; Ellis KA; Ames D; Darby D; Harrington K; Martins RN; Masters CL; Rowe C; Savage G; Szoeke C; Villemagne VL; Maruff P;
    Alzheimers Dement; 2013 Sep; 9(5):538-45. PubMed ID: 23159043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of β-amyloid positivity on cerebral metabolism in cognitively normal seniors.
    Bozoki AC; Zdanukiewicz M; Zhu DC;
    Alzheimers Dement; 2016 Dec; 12(12):1250-1258. PubMed ID: 27445158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of APOE ε4 genotype on amyloid-β, glucose metabolism, and gray matter volume in cognitively normal individuals and amnestic mild cognitive impairment.
    Li W; Li R; Yan S; Zhao Z; Shan Y; Qi Z; Lu J;
    Eur J Neurol; 2023 Mar; 30(3):587-596. PubMed ID: 36448771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between white matter hyperintensity severity and cognitive impairment according to the presence of the apolipoprotein E (APOE) ε4 allele in the elderly: retrospective analysis of data from the CREDOS study.
    Son SJ; Lee KS; Lee Y; Baek JH; Choi SH; Na DL; Seo SW; Oh BH; Hong CH
    J Clin Psychiatry; 2012 Dec; 73(12):1555-62. PubMed ID: 23146133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic interaction between APOE and family history of Alzheimer's disease on cerebral amyloid deposition and glucose metabolism.
    Yi D; Lee Y; Byun MS; Lee JH; Ko K; Sohn BK; Choe YM; Choi HJ; Baek H; Sohn CH; Kim YK; Lee DY;
    Alzheimers Res Ther; 2018 Aug; 10(1):84. PubMed ID: 30134963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease.
    Reiman EM; Chen K; Liu X; Bandy D; Yu M; Lee W; Ayutyanont N; Keppler J; Reeder SA; Langbaum JB; Alexander GE; Klunk WE; Mathis CA; Price JC; Aizenstein HJ; DeKosky ST; Caselli RJ
    Proc Natl Acad Sci U S A; 2009 Apr; 106(16):6820-5. PubMed ID: 19346482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele.
    Langbaum JB; Chen K; Caselli RJ; Lee W; Reschke C; Bandy D; Alexander GE; Burns CM; Kaszniak AW; Reeder SA; Corneveaux JJ; Allen AN; Pruzin J; Huentelman MJ; Fleisher AS; Reiman EM
    Arch Neurol; 2010 Apr; 67(4):462-8. PubMed ID: 20385913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.
    Mattsson N; Groot C; Jansen WJ; Landau SM; Villemagne VL; Engelborghs S; Mintun MM; Lleo A; Molinuevo JL; Jagust WJ; Frisoni GB; Ivanoiu A; Chételat G; Resende de Oliveira C; Rodrigue KM; Kornhuber J; Wallin A; Klimkowicz-Mrowiec A; Kandimalla R; Popp J; Aalten PP; Aarsland D; Alcolea D; Almdahl IS; Baldeiras I; van Buchem MA; Cavedo E; Chen K; Cohen AD; Förster S; Fortea J; Frederiksen KS; Freund-Levi Y; Gill KD; Gkatzima O; Grimmer T; Hampel H; Herukka SK; Johannsen P; van Laere K; de Leon MJ; Maier W; Marcusson J; Meulenbroek O; Møllergård HM; Morris JC; Mroczko B; Nordlund A; Prabhakar S; Peters O; Rami L; Rodríguez-Rodríguez E; Roe CM; Rüther E; Santana I; Schröder J; Seo SW; Soininen H; Spiru L; Stomrud E; Struyfs H; Teunissen CE; Verhey FRJ; Vos SJB; van Waalwijk van Doorn LJC; Waldemar G; Wallin ÅK; Wiltfang J; Vandenberghe R; Brooks DJ; Fladby T; Rowe CC; Drzezga A; Verbeek MM; Sarazin M; Wolk DA; Fleisher AS; Klunk WE; Na DL; Sánchez-Juan P; Lee DY; Nordberg A; Tsolaki M; Camus V; Rinne JO; Fagan AM; Zetterberg H; Blennow K; Rabinovici GD; Hansson O; van Berckel BNM; van der Flier WM; Scheltens P; Visser PJ; Ossenkoppele R
    Alzheimers Dement; 2018 Jul; 14(7):913-924. PubMed ID: 29601787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.